Older adults · Texas
Studies for adults 50 and older in Texas
These studies set a minimum age of 50 or older in their official record. Many look at conditions more common with age, and some vaccine and memory studies specifically need older participants.
98 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Austin, TX + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
A Study in Adults With Geographic Atrophy
Sitala Bio LTD
- Location
- Burleson, TX + 1 other US site
- Eligibility basics
- Ages 60+
- RecruitingPhase 1/Phase 2
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
AbbVie
- Location
- Dallas, TX + 10 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
ONL Therapeutics
- Location
- Austin, TX + 55 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompé Farmaceutici S.p.A
- Location
- Houston, TX + 13 other US sites
- Eligibility basics
- Ages 50–80
- RecruitingPhase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Astellas Institute for Regenerative Medicine
- Location
- Dallas, TX + 12 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
ADARx Pharmaceuticals, Inc.
- Location
- Austin, TX + 18 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 1/Phase 2
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Skyline Therapeutics (US) Inc.
- Location
- Katy, TX + 2 other US sites
- Eligibility basics
- Ages 50+
- RecruitingEarly Phase 1
Examining the Effects of Theta Burst TMS on Brain Connectivity and Balance Ability in Older Adults With Balance Problems
Weinberg Medical Physics LLC
- Location
- Houston, TX
- Eligibility basics
- Ages 65+
- Recruiting
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
i-Lumen Scientific AUS PTY LTD
- Location
- Fort Worth, TX + 5 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 1/Phase 2
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
4D Molecular Therapeutics
- Location
- Austin, TX + 19 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
Ocugen
- Location
- McAllen, TX
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Houston, TX + 7 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
EyeBiotech Ltd.
- Location
- Bellaire, TX + 51 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 1
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
Regeneron Pharmaceuticals
- Location
- Austin, TX + 4 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
Adverum Biotechnologies, Inc.
- Location
- The Woodlands, TX + 11 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 1/Phase 2
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
AbbVie
- Location
- Abilene, TX + 4 other US sites
- Eligibility basics
- Ages 50+
- Recruiting
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
Urotronic Inc.
- Location
- Austin, TX + 6 other US sites
- Eligibility basics
- Ages 50+ · Men only
- RecruitingPhase 3
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Eli Lilly and Company
- Location
- Beaumont, TX + 41 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2/Phase 3
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Kardigan, Inc.
- Location
- Austin, TX + 46 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or…
Ocular Therapeutix, Inc.
- Location
- Austin, TX + 7 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 1
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
GlaxoSmithKline
- Location
- Austin, TX + 11 other US sites
- Eligibility basics
- Ages 65–85
- RecruitingPhase 2
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in…
Apellis Pharmaceuticals, Inc.
- Location
- Abilene, TX + 77 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Novartis Pharmaceuticals
- Location
- Houston, TX + 29 other US sites
- Eligibility basics
- Ages 50–80